From a research result to a product hypothesis
“The data looks real. Is there a product here, and what does that change about how I work?”
The point at which a finding stops being a result and starts being a claim someone will rely on. Almost nothing about the science changes here; what changes is that the record becomes evidence, and evidence has requirements a lab notebook was never designed to meet.
WHAT THIS IS NOT
Orientation for translating research toward a regulated product — not a determination of device status, regulatory pathway, submission type or clinical adequacy, and not a substitute for qualified regulatory advice. SPEQ is independent: linked institutions, incubators and agencies are third parties, and nothing here implies affiliation, endorsement or partnership with any of them.
ARE YOU HERE?
- You have a reproducible result and someone has asked whether it could be a product
- No regulatory body knows you exist, and nothing you have done yet is wrong
- Your records were made to convince you and your collaborators, not a stranger years from now
WHAT TO DECIDE NOW
- Whether you are pursuing a product or a publication — both are legitimate, and they diverge in what they require of the record
- Who owns the underlying materials and data, which is usually an institutional question with a contractual answer
- Nothing about regulatory pathway yet. It is too early, and an early guess tends to harden into an assumption nobody revisits
START KEEPING THESE RECORDS NOW
- Provenance of every material, cell line, reagent and dataset — where it came from, under what agreement, and what it is permitted to be used for
- The conditions under which the result was produced, in enough detail that someone else could repeat it without asking you
- Version and date of any software or model used, including anything you wrote yourself
THE PROBLEM THIS ANSWERS
The framework that governs a product cannot be settled from the technology, and the team has no written position on the three things that decide it — intended use, primary mode of action and jurisdiction.
What it costs: Every downstream decision is made against a moving target. Evidence is gathered for a claim that has not been fixed, so it may not be evidence for the claim eventually made.
NOT YET MEASURED — Sustained arrivals on /tools/regulatory-pathway-orientation, or the question appearing unprompted in office-hour sessions.
WHERE THIS GOES WRONG
- Treating "we will tidy the records up later" as a plan. Provenance is the one thing that cannot be reconstructed, because the people and the paperwork move on.
- Assuming academic freedom-to-operate carries into commercial use. Material transfer agreements routinely permit research use and prohibit exactly what a product requires.
- Deciding the regulatory pathway from the technology. Pathway follows intended use, and intended use is a claim you have not written yet.
WHAT THIS DOES NOT ANSWER
- Whether the eventual product is a drug, a biologic, a device or software — this guide does not determine that, and neither should anyone until the intended use is written down
- Which regulator sees it first, which follows from the answer above and from where you intend to market
OFFICIAL SOURCES · INDEPENDENT THIRD PARTIES
The agency’s own framing of the question, which turns on intended use rather than on technology.
NIH — Intellectual Property Policy and Technology Transfer ↗Where federally funded material and data obligations are set out, which is usually where provenance questions actually get answered.
GO DEEPER ON SPEQ